Analyst Ratings For Kenvue
Portfolio Pulse from Benzinga Insights
Kenvue (NYSE:KVUE), the world's largest pure-play consumer health company, has received diverse analyst ratings ranging from bullish to indifferent. Recent analyst actions include raising and lowering price targets, with an average 12-month target of $22.5. Despite a slight revenue decline, Kenvue shows strong financial health with high net margins and ROE.
September 23, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Kenvue has received mixed analyst ratings with a 12-month price target average of $22.5, indicating a slight increase from previous targets. Despite a minor revenue decline, Kenvue's financial metrics like net margin and ROE remain strong, suggesting resilience in a competitive market.
The mixed analyst ratings and slight increase in average price target suggest a neutral short-term impact on Kenvue's stock price. The company's strong financial metrics, despite a minor revenue decline, indicate stability, which may offset any negative sentiment from the revenue dip.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100